Related to SAFC Adds 50,000 Square Feet to Jerusalem Site to Bump Up Fermentation Capabilities

• U.S. Stem Cell Companies Find Partners and Revenues Beyond the Water’s Edge
  Firms find it easier to navigate regulatory requirements in Asia as well as Europe.
  
• For Some Emerging Companies, the Road to Growth Connects the U.S. and China
  While American firms are tapping China’s size and regulatory path, Chinese biotechs are going west for money and expertise.
  
• Germany Anchors Translational Medicine Efforts with New Spending Plan and Centers
  Country hopes framework will augment alliances among its institutes as well as assuage industry drug pricing concerns.
  
• Massachusetts Sees $2B Construction Boom from the Biopharma Industry
  Growth has been built on academic expertise and fueled by tax breaks.
  
• Studies Suggest that When It Comes to Drug Development Success, Size Matters
  Higher percentage of large molecules compared to small molecules makes it to market.
  
• A SPA for PMTs
  Researchers propose a SPA strategy that can be successfully implemented to identify novel and specific inhibitors of PMTs.
  
• New Luciferins
  Researchers describe a rapid method to synthesize D-luciferin along with a novel set of electronically modified analogues.
  
• Russia Establishes Clinical Trial Hub
  Cost and speed play big roles in the country’s increased presence in the market.
  
• 10 Best U.S. Regions to Secure a Biotech Job
  GEN shows you where careers are made.
  
• Binding MoA by DPI
  Researchers investigate the application of dual-polarization interferometry (DPI) as a method for the real-time characterization of low molecular weight ligands.
  
• DuBiotech: The Silicon Valley of Biotechnology
  The Dubai Biotechnology & Research Park is open for business and aiming to catch the eye of biotech companies.
  
• Not Quite 1918, but Flu Still Deadly
  Authorities and manufacturers look ahead to new vaccines and immunization efforts while scrambling to deal with spot shortages.
  
• No Passage to India
  Private investment dearth clouds the future of the subcontinent’s fast-growing biopharma industry.
  
• Stockholm-Uppsala Region Ups the Ante
  The region bets big in the quest for international renown.
  
• Poland Invests in Biotech Infrastructure
  Will it be enough for the industry to succeed?
  
• Genzyme Plant Shutdown Could Mean up to $300M in Lost Sales
  Sales of drugs for Fabry, Gaucher’s, and Pompe diseases will take a hit.
  
• Companies Step In to Fill Gap in Enzyme Replacement Therapy for Gaucher’s
  Shortage could lead to more choices for patients sooner than expected.
  
• Dendreon’s $70M Investment in Production Capabilities Could Woo Firms without Similar Expertise
  If cell-based immune therapy Provenge receives FDA sanction, it may corner a large market share and expand the company’s prospects.
  
• Refocusing on Therapeutic Protein Production in Plants
  Recent contamination issues with Genzyme’s CHO-cell manufacturing has highlighted the advantages of plant-based techniques.
  
• High-Tech Companies Buy Into Biomanufacturing
  Samsung and Fujifilm believe such high-investment diversification will help business.